Sartorius Stedim Biotech Further Develops Its In-Situ Sterilizable Fermenter/Bioreactor BIOSTAT D-DCU

• Standardized modular design accelerates commissioning and training
• TakeOne aseptic single-use sampling system for fast and safe sampling
• Integrated CIP (Clean-in-Place) concept for efficient cleaning

Sartorius Stedim Biotech, a leading global supplier of the biopharmaceutical industry, has launched a new version of its proven stainless steel fermentor/bioreactor BIOSTAT D-DCU. The compact and modular, in-situ sterilizable system is suitable for microbial and cell cultures and is supplied in working volumes of 10 to 200 liters. Typical application areas for the BIOSTAT D-DCU include the process development and production of small-batch biopharmaceutics, vaccines, enzymes, along with antibiotics and other secondary metabolites.

Modular Design Enable Flexible Configuration from Basic Set-Up to Sophisticated Configurations
The modular design of the BIOSTAT D-DCU enables flexible configuration of the bioreactor system to meet individual customer needs. Available options range from a basic batch set-up to sophisticated configurations supporting advanced gassing and feeding strategies, WIT-Ready filter housings and automatic transfer of seed to a larger bioreactor or sterile harvest into a stainless steel vessel or single-use bag.

Thanks to its standardized components and functions, design lead times are abbreviated, which results in faster system deliveries to our customers. Furthermore, standardization simplifies operator training and process transfers to other departments and locations, and finally, speedy availability of spare parts is achieved wherever needed to keep operations running smoothly.

The bioreactor's control unit is available in a single- or twin version and can drive one or two culture vessels simultaneously and independently of each other. Their 19'' touch screen is easy to use and intuitive, which shortens training of new operators. In addition to controlling relevant process parameters like temperature, agitator speed and pressure, pH and DO (pO2), optical density etc., the system features fully automatic sterilization and cleaning functions. The novel mobile CIP unit completes the fully automatic cleaning concept of the BIOSTAT D-DCU.

Hybrid Solutions for the Entire Upstream Process
It's not only easy to connect the stainless steel bioreactor to single-use filters or bags, but also to single-use systems for media preparation or cell harvesting. What's new to the product portfolio is the TakeOne aseptic single-use sampling system that ensures safe and contamination-free sampling. This avoids complicated and time-consuming cleaning and sterilization of the sampling valve and bottle. That means that SSB can equip the entire upstream process of its customers with hybrid, perfectly matched solutions. The customer enjoys the advantages of a proven stainless steel fermenter, while benefiting from the low initial investment costs and the flexibility and speed of innovative single-use solutions.

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

For more information, visit www.sartorius.com.